Central Sleep Apnea at High Altitude.

Area of Science:

• High-altitude physiology
• Sleep medicine
• Respiratory control

Background:

• Central sleep apnea (CSA) is common at high altitudes (>2000 m), affecting most individuals above 5000 m.
• CSA severity is linked to ventilatory responsiveness, particularly to hypoxia.
• The condition arises from hypocapnia interacting with sleep stages and increased loop gain, driven by hypoxic ventilatory response.

Purpose of the Study:

• To review the mechanisms and management of central sleep apnea (CSA) at high altitude.
• To understand the impact of acclimatization on CSA.
• To explore interventions for mitigating high-altitude CSA.

Main Methods:

• Literature review of studies on high-altitude sleep apnea.
• Analysis of physiological mechanisms including hypocapnia, loop gain, and ventilatory responses.
• Examination of treatment strategies for CSA.

Main Results:

• CSA at high altitude is persistent, potentially lasting over a month at 5000 m.
• Acclimatization presents counteracting forces: increased PaO2 and cerebral blood flow (CBF) may mitigate CSA, but increased ventilatory responses can worsen it.
• Interventions like descent, oxygen, acetazolamide, and bi-level noninvasive ventilation can reduce CSA severity.

Conclusions:

• Central sleep apnea (CSA) is a significant challenge at high altitudes, influenced by complex physiological interactions.
• While acclimatization theoretically should improve CSA, its time course and effects are complex.
• Various medical interventions can effectively reduce the severity of high-altitude CSA and improve sleep quality.